- Press Releases
- Notices
Press Releases To List
-
- Feb.16.2026R & D
- Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
-
- Feb.02.2026Management / Finance
- Announcement on Financial Results for FY2025 Q3
-
- Jan.14.2026R & D
- Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
-
- Jan.13.2026R & D
- Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
-
- Dec.11.2025Sustainability
- Ono Receives Highest A-List Rating in CDP 2025 Report for Climate Change and Water Security Efforts
Notices To List
-
- Feb.04.2026Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q3 - Script
-
- Jan.15.2026Corporate
- The 44th Annual J.P. Morgan Healthcare Conference Presentation Materials Posted
-
- Nov.04.2025Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q2 - Script
-
- Sep.29.2025Corporate
- Corporate Report 2025 has been released.
-
- Aug.04.2025Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q1 - Script
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
